Publications by authors named "Matthew Germinaro"

Claim this Profile
G
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
David T Rubin, Jessica R Allegretti, Julián Panés, Nicole Shipitofsky, Shadi S Yarandi, Matthew Germinaro

Lancet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease.
Bruce E Sands, Julian Panés, Brian G Feagan, Hongyan Zhang, Marion L Vetter, Matthew Germinaro

Value Health· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Laurent Peyrin-Biroulet, Jessica R Allegretti, David T Rubin, Brian Bressler, Matthew Germinaro

Gastroenterology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease.
Brian G Feagan, William J Sandborn, Bruce E Sands, Yan Liu, Marion Vetter, Matthew Germinaro

J Patient Rep Outcomes· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
Mathieu Uzzan, Yoram Bouhnik, Maria Abreu, Harris A Ahmad, Shashi Adsul, Matthew Germinaro

J Crohns Colitis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Brian G Feagan, Bruce E Sands, William J Sandborn, Matthew Germinaro, Marion Vetter

Lancet Gastroenterol Hepatol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
William J Sandborn, Geert R D'Haens, Walter Reinisch, Julián Panés, Daphne Chan, Matthew Germinaro

Gastroenterology· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy.
Stephen C Dreskin, Matthew Germinaro, Dominik Reinhold, Xueni Chen, Brian P Vickery

Pediatr Allergy Immunol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Steven F Weinstein, Rohit K Katial, Philip Bardin, Stephanie Korn, Mirna McDonald, Matthew Germinaro

J Allergy Clin Immunol Pract· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma.
Eric D Bateman, Ratko Djukanović, Mario Castro, Janice Canvin, Matthew Germinaro

Am J Respir Crit Care Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
Guy Brusselle, Matthew Germinaro, Sivan Weiss, James Zangrilli

Pulm Pharmacol Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
Leif Bjermer, Catherine Lemiere, Jorge Maspero, Sivan Weiss, James Zangrilli, Matthew Germinaro

Chest· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of B-cell activating factor receptor deficiency with the P21R polymorphism and common variable immunodeficiency.
Matthew Germinaro, Paul Reynolds, Vijaya Knight, Rafeul Alam

Ann Allergy Asthma Immunol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis